Volume 64, Issue 1 pp. 70-76
CLINICAL RESEARCH ARTICLE

TS-HDS and FGFR3 antibodies in small fiber neuropathy and Dysautonomia

Jorge A. Trevino MD

Jorge A. Trevino MD

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Search for more papers by this author
Peter Novak MD, PhD

Corresponding Author

Peter Novak MD, PhD

Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence

Peter Novak, Department of Neurology; Brigham and Women's Faulkner Hospital, 1153 Centre Street, Boston, MA 02130, USA.

Email: [email protected]

Search for more papers by this author
First published: 01 April 2021
Citations: 13

Funding information: Brigham and Women's Hospital

Abstract

Introduction

The specificity of trisulfated heparin disaccharide/fibroblast growth factor receptor 3 (TS-HDS/FGFR3) antibodies in the diagnosis of autoimmune small fiber neuropathy (SFN) is unclear.

Methods

This was a retrospective study of patients evaluated for SFN and dysautonomia in the Brigham and Women's Faulkner Hospital Autonomic Laboratory in 2019–2020. Associations were assessed between TS-HDS/FGFR3 antibodies and SFN markers, including epidermal nerve fiber density (ENFD), sweat gland nerve fiber density (SGNFD), and autonomic dysfunction assessed by Valsalva maneuver, deep breathing, sudomotor, and tilt testing.

Results

Of 322 patients; 28% had elevated anti-TS-HDS, 17% had elevated anti-FGFR3, 96% had autonomic dysfunction, 71% had abnormal ENFD, and 49% had abnormal SGNFD. TS-HDS/FGFR3 antibodies were present in patients with autonomic dysfunction irrespective of whether they had normal or abnormal skin biopsies unless ENFD/SGNFD were combined for anti-FGFR3 seropositivity.

Discussion

TS-HDS/FGFR3 antibodies are present in patients with evidence of autonomic dysfunction. Further studies are needed to document the clinical value of these antibodies in assessment of immune mediated dysautonomia.

CONFLICT OF INTEREST

Peter Novak has received support from the Memory advancement by intranasal insulin in Type 2 Diabetes -MemAID- study; Trial Registration NCT02415556; FDA IND 107690; NIH-NIDDK R01DK103902; served as advisor - independent Contractor for Dysimmune Diseases Foundation, received speaker's honoraria from KabaFusion and Lundbeck, is a member of the Scientific Advisory Board of Endonovo Therapeutics, and has received royalties from Oxford University Press. Jorge Trevino received funding from the Memory advancement by intranasal insulin in Type 2 Diabetes -MemAID- study; Trial Registration NCT02415556; FDA IND 107690; NIH-NIDDK R01DK103902.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me